

S 3148

Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2002

Congress: 107 (2001–2003, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Oct 17, 2002

Current Status: Read twice and referred to the Committee on Finance.

Latest Action: Read twice and referred to the Committee on Finance. (Oct 17, 2002)

Official Text: <https://www.congress.gov/bill/107th-congress/senate-bill/3148>

Sponsor

Name: Sen. Lieberman, Joseph I. [D-CT]

Party: Democratic • **State:** CT • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Hatch, Orrin G. [R-UT]	R · UT		Oct 17, 2002

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Oct 18, 2002

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Biological, Chemical, and Radiological Weapons Countermeasures Research Act of 2002 - Directs the Secretary of Homeland Security to make available to manufacturers of terror weapons countermeasures, and to publish, a list of materials that may be used as weapons of mass destruction (WMD). Requires the Secretary to determine countermeasures that diagnose, treat, or prevent infection from biological agents or toxins ("countermeasures") for each item on the list.

Requires private sector entities that are engaged in certain research to register with the Department of Homeland Security if they wish to benefit from various tax, patent, procurement, liability limitations, and other incentives established under this Act. Classifies such research as: (1) countermeasures; (2) diagnostics to detect, identify, or analyze biological agents or toxins ("diagnostics"); and (3) research tools used in the laboratory ("research tools") that enable the rapid and effective development of countermeasures.

Establishes in the Treasury of the United States a "Terror Weapon Countermeasure Purchase Fund (TWCPF)" to purchase, and provide adequate payment for, countermeasures, diagnostics, and research tools.

Extends market exclusivity for new drugs that are countermeasures.

Directs the Secretary to enter into agreements to indemnify and defend persons or entities: (1) involved in the research, development, and production of countermeasures, diagnostics, or research tools purchased under the TWCPF; or (2) who face civil actions arising from human trials and research, development, and production of countermeasures certified under this Act.

Actions Timeline

- **Oct 17, 2002:** Introduced in Senate
- **Oct 17, 2002:** Sponsor introductory remarks on measure. (CR S10716-10725)
- **Oct 17, 2002:** Read twice and referred to the Committee on Finance.